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Abstract 
Only a minority of heavy drinkers progress to alcohol-related cirrhosis (ALC). The aim of this 
study was to identify common genetic variants that underlie risk for ALC. We analyzed data 
from 1,128 subjects of European ancestry with ALC and 614 heavy drinking subjects without 
known liver disease from Australia, the United States, the United Kingdom and three countries in 
Europe. Genome-wide association study (GWAS) was performed, adjusting for principal 
components and clinical covariates (alcohol use, age, sex, BMI, diabetes). We validated our 
GWAS findings using UK Biobank. We then performed a meta-analysis combining data from 
our study, the UK Biobank, and a previously published GWAS. Our GWAS found genome-wide 
significant risk association of rs738409 in PNPLA3 (Odds Ratio (OR)=2.19 (G allele), p-
value=4.93x10-17) and rs4607179 near HSD17B13 (OR=0.57 (C allele), p-value=1.09x10-10) with 
ALC. Conditional analysis accounting for the PNPLA3 and HSD17B13 loci identified a new 
protective association at rs374702773 in Fas Associated Factor family member 2 (FAF2) 
(OR=0.61 (del(T) allele), p-value=2.56x10-8) for ALC. This association was replicated in the UK 
Biobank using conditional analysis (OR=0.79, p-value=0.001). Meta-analysis (without 
conditioning) confirmed genome-wide significance for the newly identified FAF2 locus as well 
as PNPLA3 and HSD17B13. Two other previously known loci (SERPINA1, SUGP1/TM6SF2) 
were also genome-wide significant in the meta-analysis. GeneOntology pathway analysis 
identified lipid droplets as the target for several identified genes. In conclusion, our GWAS 
identified a new locus at FAF2 associated with reduced risk of ALC among heavy drinkers. Like 
the PNPLA3 and HSD17B13 gene products, the FAF2 product has been localized to fat droplets 
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Chronic alcohol use is a leading cause of cirrhosis in the Western world and is on the rise in 
many other countries. Although chronic and heavy alcohol use is a requirement for development 
of alcohol-related liver cirrhosis (ALC), only a minority of heavy drinkers progress to cirrhosis. 
Reliable risk estimates for cirrhosis among heavy drinkers are difficult to obtain, but it is often 
estimated at 10-15% after decades of heavy alcohol use (1, 2). Generally accepted risk factors for 
the development of ALC include duration and amount of alcohol consumed, female gender, and 
obesity.  
 
Many authors have suggested genetic variation in vulnerability to alcohol-related, or other types 
of liver disease. The most reported genetic variant in liver diseases is rs738409 in PNPLA3. The 
variant’s G allele is associated with increased risk for non-alcoholic fatty liver 
disease/steatohepatitis (NAFLD/NASH) (3) and with increased risk and severity for alcohol-
related liver diseases (4-6). A genome-wide association study (GWAS) of ALC, from two 
cohorts comprising approximately 700 alcohol-related cirrhotic cases and 1400 drinking controls 
without known liver disease, reported a genome-wide-significant association between rs738409 
and ALC (7). These investigators also reported association of rs58542926 (TM6SF2), and 
rs641738 (MBOAT7) with ALC (7). Additionally, Abul-Husn et al. reported an association 
between rs72613567 (HSD17B13) and alcohol-related and non-alcoholic fatty liver-related 
cirrhosis (8), although not at a genome-wide significance level. Most recently, Emdin et al. 
reported an association between rs2642438 (MARC1) and all-cause cirrhosis, including in a 
subset of patients with alcohol-related liver diseases (9). Thus, several analyses have identified 
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NASH, supporting a genetic predisposition for ALC, as well as shared genetic susceptibility with 
NASH (10). 
 
We undertook a multinational GWAS of European ancestry participants with carefully 
characterized ALC status to identify predisposing genetic factors. We enrolled subjects at high 
and low ends of the spectrum of alcohol-related liver disease, specifically excluding subjects 
with intermediate stages of disease to maximize statistical power. Cases had a history of high-
risk alcohol intake with clinically or histologically defined ALC. Controls were heavy drinkers 
without clinical evidence of liver disease. We chose drinkers without known liver disease rather 
than non-drinkers as controls to avoid the potential of finding genetic risk loci related to alcohol 
use. Our stringent eligibility criteria for this case-control design allowed for standardization of 
both the ALC subjects and of the non-liver disease subjects across enrollment sites.  
 
Material and Methods 
SUBJECTS 
GenomALC cohort 
The GenomALC study participants were recruited at clinical sites in Australia, France, Germany, 
Switzerland, the United Kingdom, and the United States using a standardized pre-defined 
protocol (11). Enrollment occurred between 2012 and 2017 with approvals from site-specific 
governing ethics committees and written informed consent from all recruited participants. All 
participants were required to have alcohol consumption of ≥80 grams per day (males) and ≥50 
grams per day (females) for at least 10 years. Controls were defined as having normal bilirubin, 
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Those with mildly elevated liver tests were included as controls if their transient elastography 
was less than 6 kPa. Cases were defined by 1) clinically evident portal hypertension or 
decompensated cirrhosis (e.g., ascites, esophageal varices), 2) Fibroscan stiffness >22kPa if AST 
<100 IU/L/>32kPa if AST 100-200 IU/L/exclude if AST >200 IU/L, or 3) liver histology 
(Metavir score of F4) on a previously-performed liver biopsy. Those with other causes of liver 
disease (e.g. viral hepatitis, hemochromatosis) or with HIV were excluded as described in detail 
previously (11). DNA was obtained from blood samples and genotyped on Global Screening 
Array v1.0 (Illumina., 5200 Illumina Way, San Diego, CA 92122). Genotype data were reviewed 
using the steps detailed in the Supplemental texts. In brief, using a GWAS data cleaning pipeline, 
genotyped SNPs were filtered for call rate, violation of the Hardy-Weinberg equilibrium (HWE) 
and minor allele frequency (MAF). Samples were checked for genotyping rate, sex, relatedness, 
and European genetic ancestry. PLINK was used to check for discordance between reported and 
genetic sex, sample relationship was calculated using --genome command and using Pi-hat value, 
we removed one sample from each pair of related individuals down to second-degree relatives. 
Genetic ancestry was determined using SNPRelate package using 1000 Genomes Project as 
reference. Additional genotypes were imputed using the Michigan Imputation Server (12). 
Additional details on GWAS data cleaning is available in the Supplement Texts under ‘Genetic 
Data Cleaning’ section. 
Laboratory of Neurogenetics (LNG) cohort 
Genotype and phenotype data from 860 heavy-drinking subjects who had given consent as part 
of two NIH screening/natural history protocols (98-AA-009; 05-AA-0121) were provided by the 
Laboratory for Neurogenetics (LNG) at the National Institutes on Alcohol Abuse and 
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were required to have alcohol consumption of ≥80 grams per day (males) and ≥50 grams per day 
(females) and excluded if they had a serious medical condition requiring ongoing treatment, 
including liver disease. Genotype data (Illumina OmniExpress Bead Chip) were cleaned and 
imputed using the same pipeline used for GenomALC. After filtering, 235 participants meeting 
the inclusion criteria were included as controls.  
 
UK Biobank cohort 
Data from the UK Biobank (https://www.ukbiobank.ac.uk/) were accessed under approval 
number 18870. Cirrhosis cases (n=530) were defined as having ICD10 code K70.3; ‘Alcoholic 
Cirrhosis of Liver’, or ICD-9 code 571.2, ‘Cirrhosis, liver, alcoholic’, and ICD10 code K70.1; 
‘Alcoholic hepatitis without ascites’ or ICD-9 code 571.1, ‘Acute alcoholic hepatitis’. Controls 
(n=10,222) were defined as having 1) reported alcohol intake of ≥80g/d (males) and ≥50g/d 
(females) and/or 2) an ICD10 diagnosis of F10 (Mental and behavioural disorders due to 
alcohol), but with no recorded diagnosis of any liver disease. Genotype data were cleaned and 
imputed by the UK Biobank investigators; we used the ‘White British’ ancestry subset of 
samples provided. After additional data cleaning (see Supplemental Text), 8,185,141 SNPs in 
439 alcohol-related cirrhosis cases and 8,364 controls were available for analysis.  
 
Additional sample description and genotype data cleaning information for the three cohorts is 
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STATISTICAL METHODS 
Genome Wide Association Tests in GenomALC 
A total of 1,128 ALC cases and 614 heavy drinking controls were available for analysis. To test 
association between each SNP and ALC (cases vs. controls), logistic regression between case-
control status and dosage value of each SNP was tested using PLINK (13). The following 
covariates were included in each regression model: 1) first ten principal components (PCs), 2) 
age, 3) sex, 4) years of excessive drinking, 5) alcohol consumed measured in grams per day, 6) 
total lifetime alcohol consumed measured in kilograms, 7) diabetes status (present/absent), and 
8) body mass index (BMI). To identify additional genetic associations beyond the two genome-
wide significant loci (rs4607179 for HSD17B13 and rs738409 for PNPLA3), we ran a 
conditional GWAS that included minor allele counts (dosage) for variants at the two loci as 
covariates. Conditional GWAS also included all covariates used in the primary GWAS along 
with the two dosage values. The p-value threshold for genome-wide statistical significance was 
set at 5 x 10-8. 
 
GWAS in UK Biobank data 
The data were analyzed with FaST-LMM (14), a mixed model method that computes a kinship 
matrix to adjust for relatedness/population stratification and infers any missing genotypes at a 
SNP based on the genotypes of other samples at that SNP. Cases (231) and drinking controls 
(8,364) that had all the clinical covariates (age, sex, type 2 diabetes mellitus (T2DM) status, 
BMI, and current daily alcohol intake (in grams)) were included in a GWAS that mirrored the 
primary analysis performed in GenomALC cohort. To mirror the GenomALC conditional 
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the minor allele counts at rs738409 and rs4607179 as covariates along with the clinical variables. 
ORs were obtained from logistic regression in PLINK including all relevant covariates, and 
confidence intervals were calculated from back-transformation of FaST-LMM p-values and 
PLINK ORs. 
As a sensitivity analysis, we also conducted a GWAS of cases and controls that excluded those 
that did not meet the criteria of current alcohol intake per day ≥ 80g/day (males) and ≥ 50g/day 
(females), resembling the GenomALC criteria. This GWAS included a total of 231 cases and 
5,361 controls and adjusted for the same set of covariates used in the primary GWAS. 
 
Meta-analysis 
Meta-analysis of our primary GWAS results from GenomALC, the UK Biobank, and the GWAS 
summary statistics from a published GWAS of ALC (7) was conducted using METAL (15) with 
genomic control option. Summary statistics for the published GWAS (7) were obtained from 
http://gengastro.med.tu-dresden.de/suppl/alc_cirrhosis/. 
 
Gene-set enrichment analysis 
We used enrichment analysis (16) from Gene Ontology (17, 18) to identify potential pathways 
shared by genes identified in our GenomALC GWAS analysis. Using the genes that includes or 
are nearby the SNPs with p-values less than 5x10-6 from our primary GWAS analysis, we 
identified 15 genes for enrichment analysis. We performed enrichment analysis for molecular 
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Results 
PRIMARY GWAS ANALYSIS 
The primary GenomALC GWAS analysis identified two genome-wide significant associations 
(Figure 1, Supplementary Figure S1). rs738409 on chromosome 22 (chr22), located in PNPLA3, 
was significantly associated with increased risk of ALC, with a p-value of 4.93x10-17 and an OR 
of 2.19 (95% confidence interval (CI), 1.81 - 2.54) for each copy of the G allele. rs4607179 on 
chr4, located near HSD17B13, was associated with lower risk of ALC with a p-value of 1.09x10-
10 and OR of 0.57 for each copy of the C allele (95% CI, 0.48 - 0.62) (Table 1). A list of all SNPs 
with p-values less than 5x10-6 and their association test results are shown in Supplementary 
Table S1. Age, sex, and 10 PCs adjusted GWAS analysis result of GenomALC and additional 
controls from LNG is shown in Supplementary Figure S2 and Table S2. Descriptive statistics of 
the GenomALC cohort are shown in Table 2 and UK Biobank and LNG are shown in Table S3. 
Primary GWAS analysis results from UK Biobank and sensitivity analysis, performed on 
controls reporting current alcohol use >80/50 grams/day are shown in Supplementary Tables S4 
and S5, respectively. 
 
CONDITIONAL GWAS ANALYSIS 
To identify additional genetic associations, we performed a conditional GWAS that included 
minor allele counts (dosage) for variants in the two genome-wide significant loci (rs4607179 for 
HSD17B13 and rs738409 for PNPLA3) from the primary GWAS analysis as covariates along 
with the previously included covariates. The conditional GWAS analysis identified genome-wide 
significant association for rs374702773 (FAF2) on chr5 with a p-value of 2.56x10-8 and an OR 
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Figure S3, Table 1). Association test results for both primary and conditional GWAS analyses 
for the FAF2 locus from GenomALC are shown in Supplementary Table S6. Figure 3 shows a 
LocusZoom (19) plot of rs374702773 and nearby variants. rs374702773 was not available in the 
UK Biobank data, instead we tested four variants in strong LD (D’≥0.9 & r2≥0.6) with it. 
Linkage disequilibrium (LD) values among variants are shown in Supplementary Table S7. In 
the conditional analysis of the UK Biobank, rs11134977 showed the strongest association with 
ALC (OR=0.79, p-value of 0.001), other SNPs (rs11027, rs12514451, rs34152523) in LD with 
rs374702773 showed similar OR and p-value. (Supplementary Table S6). We tested for 
interaction between FAF2 locus (rs374702773 and 4 SNPs in LD) and PNPLA3 (rs738409) and 
FAF2 locus and HSD17B13 (rs4607179) in GenomALC. None of the interaction terms were 
statistically significant (p-values >0.44) (Table S8). 
 
META-GWAS OF THREE STUDIES 
Meta-analysis of results from GenomALC, UK Biobank, and a previously published GWAS of 
alcohol-related liver cirrhosis (7) identified five independent genome-wide significant 
associations with ALC (Figure 4, Supplementary Figure S4). Summaries of top associated SNPs 
from each locus are shown in Table 1 and all SNPs with p-values less than 5x10-6 are shown in 
Supplementary Table S9. In the meta-analysis, the most significant association at FAF2 was for 
rs11134977 (p-value = 1.56 x 10-8), which is in LD with rs374702773 in FAF2. In addition to 
associations at the HSD17B13, PNPLA3, and FAF2 loci, we identified two additional genome-
wide significant associations, rs28929474 (chr14:94,844,947, SERPINA1, OR 1.90, 95% C.I. 
1.52-2.38, p-value=1.99x10-8) and rs10401969 (chr19:19,407,718, SUGP1, OR 1.49 95% C.I. 
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Supplementary Figure S5. Meta-analysis of Age, sex, and 10 PCs adjusted GWAS in 
GenomALC+LNG and UK Biobank and published GWAS from Buch et al. cohorts is available 
in Supplementary Figure S6 and Table S10. 
GENE ENRICHMENT ANALYSIS 
Gene enrichment analysis for biological process and cellular component showed a significant 
enrichment for lipid droplet and its organization among the 15 genes (Supplementary Table S11). 
Enrichment for biological process was observed for lipid droplet organization (>100-fold, 
FDR=0.003) and cellular component (>70-fold, FDR=0.020) (Table 3).  
 
Discussion 
This is the largest-to-date GWAS for alcohol-related cirrhosis, and the only multi-center GWAS 
of prospectively enrolled subjects meeting strict, protocol-defined criteria for heavy drinking, 
and for alcohol-related cirrhosis or no known liver disease.  We also conducted the first GWAS 
meta-analysis in ALC contrasting clinically defined groups of cases and heavy drinking controls 
from GenomALC, the UK Biobank, and a previously published GWAS on ALC (7). We report a 
new genome-wide association with ALC; rs374702773 located in Fas Associated Factor family 
member 2 (FAF2), with the C (minor) allele showing a protective effect. Additionally, we 
replicated the association between rs738409 (PNPLA3) and ALC (7) strengthening previous 
reports (8, 20). We also replicated an association between HSD17B13 locus and ALC by 
identifying a genome-wide significant association between ALC and rs4607179 (p-
value=1.09x10-10). Meta-analysis also identified two additional genome-wide significant 
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disequilibrium block that spans multiple genes including SUGP1 and TM6SF2. However, we did 
not find genome-wide significance for rs641738 or any other SNPs in MBOAT7 (primary GWAS 
p-value=5.31x10-03, meta-analysis p-value=4.03x10-05) which was reported by Buch et al (7). A 
recently reported association of rs2642438 in MARC1 gene and cirrhosis (9) was also not 
genome-wide significant in our meta-analysis (OR=0.81, p-value=7.54x10-06) nor in GenomALC 
GWAS (OR=0.79, p-value=0.006), but the effect was in the same direction. 
FAF2 represents a novel locus affecting genetic risk for ALC. This association became genome-
wide significant for rs374702773 in our GenomALC cohort after accounting for the effects of 
rs738409 (PNPLA3) and rs4607179 (near HSD17B13) (Supplementary Table S6). We also 
replicated this association using UK Biobank cohort (OR=0.79, p-value=0.001 for rs11134977). 
Using the larger sample size available in the meta-analysis of GenomALC, UK Biobank, and 
Buch et al (7), this association was found without conditional analysis (OR=0.79, p-
value=1.56x10-08 for rs11134977). We did not observe interaction between FAF2 locus and 
PNPLA3 or HSD17B13 loci (Supplementary Table S8). Although this may indicate that these 
loci act independently, our study was not powered enough to detect interactions. These variants 
in FAF2 are in strong LD and represent the same association. Also known as UBDX8, FAF2 is a 
sensor of intracellular levels of long-chain unsaturated fatty acids (21). In the presence of 
unsaturated fatty acid, UBXD8 binds to adipose triglyceride lipase (ATGL), the major 
triglyceride hydrolyzing enzyme, and dissociates it from its activator α/β hydrolase domain 5 
(ABHD5, also known as comparative gene identification-58 [CGI-58]). This dissociation from 
ABHD5/CGI-58 inhibits triacylglycerol hydrolysis in lipid droplets (21, 22). This biochemical 
pathway, that is, binding to ABDH5/CGI-58 and inhibiting triglyceride hydrolysis in lipid 
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steatosis (23, 24). Thus, FAF2 fits into the current proposed genetic pathways that affect 
hepatocyte lipid metabolism. However, FAF2 also regulates SREBP-1 activation and 
triacylglycerol synthesis from diacylglycerol (DAG) by DAG acytltransferase (21). The role and 
molecular function of the FAF2 associated variant and those SNPs in LD with it, are yet to be 
explored. Thus, the actual role of FAF2 in ALC risk will require a better understanding of the 
pathophysiology of liver injury by FAF2 and other implicated genes.   
Meta-analysis found genome-wide significance for association between rs28929474, a missense 
variant of SERPINA1, and ALC. SERPINA1 codes for the α-1-antitypsin (AAT) protein, with 
rs28929474 (Glu366His) coding for the Z variant of α-1-antitypsin. The Z variant causes 
conformational rearrangement of α1-antitrypsin, affecting its degradation by proteases (25, 26). 
Homozygosity for the Z variant of SERPINA1 leads to AAT deficiency (27, 28) and increased 
risk for cirrhosis. Although this is a variant with low MAF, there is independent evidence that it 
contributes to the risk of alcohol-related liver disease and cirrhosis. Heterozygosity of this 
variant has also been associated with portal hypertension (29) and cystic fibrosis-related liver 
disease (30). Abul-Husn et al. (8) and Chen et al. (31) reported rs28929474 association with 
alcohol-related liver disease/cirrhosis and non-alcoholic liver diseases using candidate variant 
analysis and a GWAS level significance with liver transaminases. Strnad and colleagues reported 
an association between the Z variant heterozygous carriers and cirrhosis in NAFLD (OR=7.3, 
p<0.0001) and in alcohol misusers (OR=5.8, p<0.0001) (32). Although none of these 
associations approached GWAS-level significance, their findings are in the same direction as our 
report. Taken together, this is a new disease risk associated with the AAT Z-variant gene product 
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We extended an association between HSD17B13 (17-β-hydroxysteroid dehydrogenase type 13) 
locus and liver disease reported previously. Although not at genome-wide significance level, 
these authors reported that the A allele (minor allele) of rs72613567 showed protective effect 
against NAFLD and/or alcohol-related liver diseases including cirrhosis and hepatocellular 
carcinoma (8). However, most recently, another group reported GWAS significance for 
HSD17B13 associated with protection against NAFLD (33). In our discovery GWAS of 
GenomALC we found genome-wide significance for rs4607179 near HSD17B13. Our meta-
analysis confirmed significance for SNPs in HSD17B13 and risk for ALC; we observe protective 
effect of the C allele of rs4607179 on ALC at genome-wide significance level (OR=0.80, 
p=1.39x10-08). Although the detailed biological function of HSD17B13 is not fully understood, it 
too is known to be associated with hepatic lipid droplets (34) and circulating triglyceride and 
high density lipoprotein levels (35, 36), suggesting overlapping mechanisms in ALC and other 
complex liver diseases.  
We replicated the association between ALC and rs738409, which codes for a missense mutation 
in PNPLA3. rs738409 had the strongest statistical association and the highest OR among the 
genome-wide significant SNPs (OR=2.19, p-value=4.93x10-17). This locus has been associated 
with risk for NAFLD, alcohol-related liver disease, and HCC in several meta-analyses (37-40). 
PNPLA3 is a lipase found on the surface of triglyceride droplets in hepatocytes. The variant 
PNPLA3 protein may increase hepatic steatosis by increasing dissociation of ABDH5/CGI-58 
from adipose triglyceride lipase, thereby inhibiting the triglyceride catabolism by ATGL (23). In 
addition, the half-life of the rs738409 variant PNPLA3 protein on the lipid droplet appears 
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Our meta-analysis found genome-wide significance for rs10401969 near SUGP1 on chr19 
(OR=1.49 for C allele, p-value=2.40x10-09). rs1041969 has been proposed to modulate activity 
of 3-hydroxy-3-methylglutaryl-CoA reductase (also known as HMG-CoA reductase), the rate 
limiting enzyme for cholesterol synthesis. rs10401969 has been reported to show associations 
with plasma LDL cholesterol level, coronary artery disease, hepatic fat in obese patients (41), 
and elevated ALT in heavy alcohol drinkers (42), suggesting that SUGP1 may be directly related 
to genetic risk for ALC. However, SUGP1 is part of a locus with multiple genes and this intron 
variant is in strong LD (r2 ~0.95 in Europeans) with variants located in nearby TM6SF2 
(Supplementary Figure S5), a locus which has been associated with ALC (7), NAFLD (43-45), 
cirrhosis/steatosis/fibrosis among chronic hepatitis C patients (46), and impaired lipid synthesis 
(47). Thus, it is not clear whether this variant implicates SUGP1 as a potential underlying gene 
for risk of cirrhosis or is a marker for TM6SF2. 
One common thread among our new and replication findings is the involvement of genetic 
variants in lipid biology, particularly triglyceride metabolism. Enrichment analysis using 
GeneOntology (17) identified lipid droplet cellular components and lipid droplet organization 
biological processes among the genes identified by GWAS. The genes involved in the process 
from our list of candidate genes were HSD17B13, PNPLA3, and FAF2. However, these genes 
have pleotropic effects: FAF2 also regulates SREBP-1 activation and triacylglycerol synthesis 
(21) while HSD17B13 has retinol dehydrogenase activity (25). Thus, defining the actual role of 
these genes in ALC will depend on a better understanding of lipid droplet biology, and other 
biochemical pathways, in the pathophysiology of liver injury especially for non-alcohol related 
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This GWAS has potential limitations. Despite being the largest available cohort for ALC, the 
size of our sample for a GWAS of common variants imposes a limit on the power to detect 
associations with weaker effect sizes. Second, although the trend for the odds ratios in the UK 
Biobank cohort is in the same direction as for GenomALC, the strength of the association was 
weaker. We suspect the weaker association may be due to the smaller number of cases in UK 
Biobank and expanded definition of heavy drinking controls in the UK Biobank as compared 
with GenomALC. Using stricter drinking criteria for controls, in our secondary and sensitivity 
analysis in the smaller UK Biobank cohort, we observed similar association results (Figure S8).  
Overall, we report a new genetic association between FAF2 and ALC. This locus is functionally 
linked to two previously reported loci (PNPNA3 and HSD17B13) by a biological pathway that 
governs lipid droplet organization. We also report increased risk for ALC in heterozygous 
carriers of the SERPINA1 Z variant. Taken together, our findings suggest that risk of developing 
ALC is, in part, related to genetic factors, especially genetic factors regulating lipid homeostasis, 
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Table 1 
Genome-wide significant associations from primary GWAS analysis. 
Top associations at significant loci from GenomALC GWAS 












4 88,214,144 rs4607179 Intergenic HSD17B13 C 0.24 1128 / 614 0.57 0.48-0.62 1.09x10-10 
5§ 175,894,130 rs374702773 Intronic FAF2 del(T)7 0.49 1128 / 614 0.61 0.51-0.73 2.56x10-08 
22 44,324,727 rs738409 Missense PNPLA3 G 0.39 1128 / 614 2.19 1.81-2.54 4.93x10-17 
            
Top associations at significant loci from meta-analysis of GenomALC, UKB, and Buch et al. 












4 88,230,100 rs10433937 Intronic HSD17B13 G 0.25 2071 / 10444 0.78 0.71-0.84 2.85 x 10-09 
5 175,904,141 rs11134977 Intronic FAF2 C 0.46 2071 / 10444 0.79 0.72-0.85 1.56x10-08 
14 94,844,947 rs28929474 Missense SERPINA1 T 0.02 2071 / 10444 1.9 1.52-2.38 1.99x10-08 
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22 44,340,904 rs2294915 Intronic PNPLA3 T 0.32 2071 / 10444 2.07 1.89-2.27 1.28 x 10-53 
 Chr (Chromosome), BP (Base Position), rsID (reference SNP cluster ID), Type (type of base substitution), effect allele (coded allele), 
effect allele frequency (allele frequency of the effect allele in GenomALC cohort), N cases/controls (number of cases / number of 
controls), L95-U95% C.I. (lower and upper 95% confidence interval). 
§ The significant result for the chromosome 5 locus in GenomALC GWAS was obtained after including minor allele counts for 
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Table 2 
Phenotypic values among GenomALC cohort. 
 GenomALC Cases GenomALC Controls 
N 1128 614 






























Alcohol consumed in grams 
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Total lifetime alcohol 
consumed in kilograms, 





1 Age for cases (cirrhosis) is calculated as age at first diagnosis of cirrhosis. Age for controls is age at which they enrolled in this trial.  
SD stands for standard deviation. N indicates number of individuals. Q1 is first quartile and Q3 is third quartile. GenomALC Cases are 
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Table 3 
Gene Ontology based enrichment analysis results 
  
Number of known 
genes in GO 
Number of 
genes in the 
list 




Lipid droplet  
(cellular component) 
81 3 0.04 70.69 + 9.94E-06 0.020 
Lipid droplet organization  
(biological process) 
21 3 0.01 > 100 + 2.15E-07 0.0034 
Number of known genes in GO (number of genes with annotated function in Gene Ontology database), Number of genes in the list 
(number of genes from the input list (also see Supplementary Table 10) that have the same annotated function from Gene Ontology), 
Expected (expected number of genes in the list from a random set of genes with same size as input list), +/- (increase/decrease in 
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Figure 1
 
Manhattan plot of primary GWAS analysis of GenomALC. The plot shows significant association of SNPs on chromosomes 4 
(HSD17B13) and 22 (PNPLA3). Vertical axis shows -log10 transformed p-value of each tested SNP after adjusting for age, sex, 
diabetes (yes/no), BMI, years of excessive drinking, alcohol consumed in grams per day, total lifetime alcohol consumed in kg, and 
ten principal components. Horizontal solid grey line shows genome-wide significance level (p=5x10-08), dotted grey line shows 
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Figure 2 
  
Manhattan plot of secondary GWAS analysis of GenomALC. After accounting for minor allele counts (dosage) for variants in 
rs4607179 near HSD17B13 and rs738409 in PNPLA3, secondary analysis in GenomALC shows significant association of SNPs on 
chromosome 5 (FAF2). Vertical axis shows -log10 transformed p-value of each tested SNP after adjusting for rs4607179, rs738409, 
age, sex, diabetes (yes/no), BMI, years of excessive drinking, alcohol consumed in grams per day, total lifetime alcohol consumed in 
kg, and ten principal components. Horizontal solid grey line shows genome-wide significance level (p=5x10-08), dotted grey line 
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Figure 3 
 
LocusZoom plot of rs374702773 and nearby SNPs on chromosome 5. From conditional analysis of GenomALC data we identified 
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Figure 4 
 
Manhattan plot of meta-analysis of GenomALC, UK Biobank, and Buch et al. Meta-analysis shows significant association of 
SNPs on chromosomes 4 (HSD17B13), 5 (FAF2), 14 (SERPINA1), 19 (TM6SF2/SUGP) and 22 (PNPLA3). Vertical axis shows -log10 
transformed p-value of each SNP from meta-analysis including GenomALC and UKB cohort GWASs adjusting for age, sex, diabetes 
(yes/no), BMI, years of excessive drinking, alcohol consumed in grams per day, total lifetime alcohol consumed in kg, and ten 
principal components and published results from Buch et al.. Solid grey line shows genome-wide significance level (p=5x10-08), 
dotted grey line shows suggestive level (p=5x10-6). 
